PARTIAL-PURIFICATION OF THE 5-HYDROXYTRYPTOPHAN-REUPTAKE SYSTEM FROM HUMAN BLOOD-PLATELETS USING A CITALOPRAM-DERIVED AFFINITY RESIN

被引:31
作者
BIESSEN, EAL
HORN, AS
ROBILLARD, GT
机构
[1] STATE UNIV GRONINGEN,DEPT PHYS CHEM,9700 AB GRONINGEN,NETHERLANDS
[2] STATE UNIV GRONINGEN,INST BIOSON,9700 AB GRONINGEN,NETHERLANDS
[3] STATE UNIV GRONINGEN,SUBFAC PHARM,DEPT MED CHEM,9700 AB GRONINGEN,NETHERLANDS
关键词
D O I
10.1021/bi00465a029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a procedure for the synthesis and application of a citalopram-derived affinity resin in purifying the 5HT-reuptake system from human blood platelets. A two-step scheme has been developed for partial purification, based on wheat germ agglutinin-lectin (WGA) affinity and Citalopram affinity chromatographies. Upon solubilization of the carrier with 1% digitonin, a 50–70-fold increase in specific [3H]imipramine binding activity with a 70% recovery could be accomplished through WGA-lectin chromatography. The WGA pool was then subjected to affinity chromatography on citalopram-agarose. At least 90% of the binding capacity adsorbed to the column. Specific elution using 10 µM Citalopram resulted in a 22% recovery of binding activity. A 10000-fold overall purification was obtained by using this two-step procedure. Analysis of the fractions on SDS-PAGE after 125I labeling revealed specific elution of 78- and 55-kDa proteins concomitant with the appearance of [3H]imipramine binding activity. The pharmacological profile of the partially purified reuptake system correlated well with that derived from the crude membrane-bound reuptake system, suggesting a copurification of the 5HT binding activity and [3H]imipramine binding activity. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:3349 / 3354
页数:6
相关论文
共 16 条
[1]   EVIDENCE FOR THE EXISTENCE OF AT LEAST 2 DIFFERENT BINDING-SITES FOR 5HT-REUPTAKE INHIBITORS WITHIN THE 5HT-REUPTAKE SYSTEM FROM HUMAN-PLATELETS [J].
BIESSEN, EAL ;
NORDER, JA ;
HORN, AS ;
ROBILLARD, GT .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (20) :3959-3966
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
CESURA AM, 1983, EUR J PHARMACOL, V96, P23
[4]   MOLECULAR ASPECTS OF THE IMIPRAMINE RECEPTOR [J].
DAVIS, A .
EXPERIENTIA, 1984, 40 (08) :782-794
[5]   SOLUBILIZATION AND CHARACTERIZATION OF THE 5-HYDROXYTRYPTAMINE TRANSPORTER COMPLEX FROM RAT CEREBRAL CORTICAL MEMBRANES [J].
HABERT, E ;
GRAHAM, D ;
LANGER, SZ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 122 (02) :197-204
[6]  
HUMPHREYS CJ, 1988, MOL PHARMACOL, V33, P657
[7]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+
[8]   HIGH-AFFINITY BINDING OF [H-3]LABELED PAROXETINE AND [H-3]IMIPRAMINE TO HUMAN-PLATELET MEMBRANES [J].
MELLERUP, ET ;
PLENGE, P ;
ENGELSTOFT, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 96 (3-4) :303-309
[9]   SIZE DETERMINATION OF BINDING POLYMERS FOR [H-3]IMIPRAMINE AND [H-3] PAROXETINE IN HUMAN-PLATELET MEMBRANES [J].
MELLERUP, ET ;
PLENGE, P ;
NIELSEN, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 106 (02) :411-413
[10]   SOLUBILIZATION AND PARTIAL-PURIFICATION OF THE HIGH-AFFINITY [H-3] IMIPRAMINE BINDING-SITE FROM HUMAN-PLATELETS [J].
REHAVI, M ;
SKOLNICK, P ;
PAUL, SM .
FEBS LETTERS, 1982, 150 (02) :514-518